Even though we have demonstrated a higher risk of NAION in persons with T2D exposed to once-weekly semaglutide, it is important to keep in mind that use of semaglutide comes with substantial advantages for patients as given by the improved glycemic control, reduction in risk of cardiovascular disease as well as the beneficial effects of weight loss [1]
Therapeutic applications SLU-PP-332 and 5-amino-1mq have been studied for their potential in treating various conditions
The question of whether tirzepatide gives you energy is answered differently by different patients, but the metabolic improvements, better blood sugar stability, reduced inflammation, and weight loss all contribute to higher baseline energy in many cases
Orforglipron (oral GLP-1 Eli Lilly) is expected to receive FDA approval over the next year
However, a high-fibre, whole-food diet, regular exercise, adequate sleep, and stress management can naturally support your bodys own GLP-1 production and improve metabolic health